India Cord Stem Cell Banking Market is expected register a healthy CAGR of 12.6% in the forecast period of 2019 to 2026. The years considered for study are mentioned below:
Access Full Report at https://databridgemarketresearch.com/reports/india-cord-stem-cell-banking-market
India cord stem cell banking market is a highly consolidated market which includes specific number of key players as well as local players. The market has witnessed various strategic developments owing to favourable market scenario. The market has a prominent growth in upcoming years due to increasing birth rate and increasing prevalence of beta-thalassemia and other disorders.
The market has witnessed developments in terms of merger and acquisitions or product launches to enhance the product portfolio to meet the rising demand of innovative technology. For instance, In August 2018, LifeCell acquired Fetomed Laboratories, a provider of clinical diagnostics services. The acquisition is for enhancement in mother & baby diagnostic services that strongly complements stem cell banking business. This acquisition was funded by the internal accruals which is aimed to be the India’s’ largest mother & baby preventive healthcare organisation.
Lifecell dominated the India cord stem cell banking market in the year 2018. The other players in the market include Cordlife Group Limited, Mycord (CelluGen Biotech Pvt. Ltd.), Reliance Life Sciences, Cryoviva India, Global Cord Blood Corporation, Cryo-Cell International, Inc., REGROW BIOSCIENCES PVT LTD, ReeLabs Pvt. Ltd. and others.
Lifecell is headquartered in Tamil Nadu was founded in 2004. The company is engaged in providing diagnostic and preventive healthcare solutions for mother as well as babies in the country. The company provides services such as biobank, biologics and diagnostics. The company is India based and has a subsidiary Fetomed Laboratories.
In March 2017, Lifecell launched Baby Cord Share. It is a community stem cell banking that fulfils the need of people and contains large inventory of stem cells in India. Baby Cord Share provides unique benefits of both private as well as public banks. This service was launched to raise the chances of finding a matching donor.
Cordlife Group Limited:
Cordlife Group Limited headquartered in Bizhub, Singapore was founded in 2001. The company focused on providing cord tissue services includes processing, testing & storages and high quality products. The company has its business segment and they are Banking and Diagnostics.
In October 2015, Cordlife received an award 2015 Frost & Sullivan Singapore Stem Cell Banking Company of the Year. An award for contribution towards developing stem cell banking industries in Singapore. This award acts as a validation of the Cordlifes’ ongoing contributions in the stem cell banking.
It has its global networks in the Myanmar, Vietnam, India, Thailand, Indonesia, Philippines, China, Hong Kong and Malaysia. It operates through its subsidiaries such as Stemlife Berhad (Malaysia), HealthBaby Biotech (Hong Kong) Co., Ltd., CS Cell Technologies Pte. Ltd (Singapore)., Cytomatrix LLC. (U.S.), Cordlife Persada, CordLife (Hong Kong), and Others.
GLOBAL CORD BLOOD CORPORATION:
Global cord blood corporation is headquartered in Hong Kong was founded in 2003. The company is leading provider of cord blood banking services. The company operates through its business and they are Cord blood processing fees, Cord blood storage fees, Fees derived from the provision of donated cord blood for transplantation and research and others. The company is operated by around 1,261 employees (As of December 31, 2019).
The company has its global networks in Singapore, Hong Kong, India, Indonesia, Malaysia and the Philippines. It operates through its subsidiaries such as Brilliant China Healthcare Investment Limited(China), Zhejiang Lukou Biotechnology Company Limited(China), Beijing Jiacheng Hong Biological Technologies Co., Ltd. (China), Zhejiang Provincial Blood Center.(China).